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Abstract
Apart from acute and chronic blood pressure lowering, we have no specific medications to prevent intracerebral haemorrhage
(ICH) or improve outcomes once bleeding has occurred. One reason for this may be related to particular limitations associated
with the current pre-clinical models of ICH, leading to a failure to translate into the clinic. It would seem that a breakdown in the
‘drug development pipeline’ currently exists for translational ICH research which needs to be urgently addressed. Here, we
review the most commonly used pre-clinical models of ICH and discuss their advantages and disadvantages in the context of
translational studies. We propose that to increase our chances of successfully identifying new therapeutics for ICH, a bi-
directional, 2- or 3-pronged approach using more than one model species/system could be useful for confirming key pre-
clinical observations. Furthermore, we highlight that post-mortem/ex-vivo ICH patient material is a precious and underused
resource which could play an essential role in the verification of experimental results prior to consideration for further clinical
investigation. Embracing multidisciplinary collaboration between pre-clinical and clinical ICH research groups will be essential
to ensure the success of this type of approach in the future.
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Introduction
Stroke is the second highest cause of death worldwide,
surpassed only by ischaemic heart disease [1]. The most devas-
tating sub-type of stroke, intracerebral haemorrhage (ICH), ac-
counts for 10–20% of all strokes in high-income countries,
whilst incidences increase in central and East Asia and sub-
Saharan Africa [2]. ICH has a mortality rate of 40% at 1-
month post-ictus, coupled with a higher loss of disability
adjusted life years, exceeding that of ischaemic stroke despite
lower prevalence [1, 3]. Knowledge of themolecular pathophys-
iology surrounding haemorrhagic stroke has vastly increased in
recent years, with a plethora of reviews describing the primary
and secondary injury phases [4–9]. Key modifiable risk factors
for ICH are well recognised, and addressing these can reduce
incidence [3, 10–14]. There is still, however, a complete lack of
specific treatments available to improve outcomes following
ICH, despite many drugs showing efficacy in preclinical models
[18]. Therefore, ICH treatment is focussed on quick diagnosis
followed by reversal of anticoagulants, blood pressure manage-
ment and surgery in carefully selected patients as determined by
guidelines for the management of spontaneous ICH [15–18].
One reason for the current lack of specific treatments in ICH
may be due, in part, to specific limitations associated with the
most commonly used existing pre-clinical models of the disease,
including constraints related to generating spontaneous brain
haemorrhages, difficulties in observing brain pathologies in live
animals and sub-optimal experimental study design [19]. It
would seem, therefore, that a breakdown in the current ‘drug
development pipeline’ exists for ICH.As such, there is an urgent
requirement to rethink our strategies for translational ICH re-
search so that we can investigate new therapeutic avenues for
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future patient treatments, as highlighted in the Haemorrhagic
Stroke Academia Industry (HEADS) initiative [20].This review
reinforces some of the priorities raised by HEADS, and how
these may be implemented within preclinical ICH research, with
our main focus highlighting the need for a more efficient, multi-
directional pipeline. A more strategic approach to ensure the
most appropriate models/systems are selected for each phase
of the pre-clinical pipeline (such as studying the occurrence of
bleed/risk factors, injury responses or treatments) would be ben-
eficial (Fig. 1). To aid with this decision, the current pre-clinical
ICH models will be discussed, including their advantages, dis-
advantages (see Table 1) and how translational ICH research
may be potentially strengthened by adopting multiple models
in parallel and embracing multidisciplinary collaboration.
In Vitro Models
In vitro studies dominate the start of the pre-clinical pipeline,
where they are commonly used to complement the work from
in vivo studies, especially when a pharmacological agent is
being tested in rodents. The in vitro work can provide vital
information on the mechanism of action, and the effects of the
compound on a particular cell type, thus demonstrating the
advantages of drug screening in vitro [21–28]. Typically, pri-
mary cortical neurons, microglia, astrocyte, mixed glia cul-
tures or endothelial cell cultures are used to emulate the effects
of blood on various brain specific cells that are affected fol-
lowing ICH. This can be beneficial for characterising the sub-
sequent response to blood molecules in individual cell types,
but less useful for identifying interactions between different
brain resident cells. Further advantages of using cell-based
systems include the relative ease of genetic manipulation, by
using siRNA, gene editing, adenoviruses or plasmid transfec-
tions to knock down or over-express various anti- or pro-
inflammatory genes or receptors, thus enabling further char-
acterisation of the neuroinflammatory response in a relatively
small time period [23, 25–27, 29].
The most conventional approach to producing an in vitro
model of ICH is by stimulating the cells with a blood compo-
nent to mimic the effects of intraparenchymal haemorrhage on
brain resident cell types. The serine protease thrombin is acti-
vated during coagulation, and has been used to stimulate
microglial cultures to determine their response to transforming
growth factor β1 (TGF-β1) [30]. Oxyhaemoglobin (oxyHb)
and haemoglobin (Hb) have been used to increase understand-
ing of less common cell death mechanisms, such as
necroptosis and ferroptosis [23, 24]. Furthermore, whole
blood from donor mice has been used with the aid of a porous
membrane insert to stimulate primary cortical neurons to al-
low observation of the full haemotoxic response, specifically
erythrocyte lysis and haemoglobin release [31]. However, the
most widely used method utilises haemin, the oxidised form
of haem, which upon erythrocyte lysis is released from
haemoglobin and has been shown to contribute to secondary
brain injury following ICH [21, 22, 24–29, 32–34].
One challenge associated with these in vitro models is
maintaining relevance to the complexity of the human condi-
tion. Following ICH, brain tissue is exposed to approximately
10 mM of haemin, whilst the concentrations used in vitro
rarely exceeds 100-μM haemin [29]. Furthermore, individual
cell types can exhibit differences in their sensitivity to haemin.
This may potentially confound downstream analyses, but
could also provide interesting insight into specific functions
Fig. 1 ICH timeline. This timeline represents the major factors which can
be studied in pre-clinical ICHmodels/systems.Mechanisms that underpin
ICH risk can be explored in spontaneous ICH models, such as hyperten-
sive rodents and zebrafish models. Secondary injury progression can be
readily observed in all the pre-clinical models, and observations can also
be verified in patient tissue such as serum and post-mortem brains. Lastly,
potential treatments can be tested across all pre-clinical animal and cell
models, where novel candidate therapeutics could be identified through
high-throughput screens (e.g. in vitro, zebrafish) and subsequently veri-
fied in a mammalian system
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of particular cell types. For example, microglia are less vul-
nerable to haemin due to their ability to upregulate inducible
nitric oxide synthase and haem oxygenase-1 [33]. Goldstein
and colleagues hypothesised that in an intact central nervous
system (CNS), the toxicity propagated by haemin could be
dampened by endogenous antioxidants or other compounds
which are not present in these specific cultures, thereby allud-
ing to why such low concentrations of haemin has to be used
experimentally [34]. Moreover, only stimulating cells with
one blood component do not allow for the full effects of
haemotoxicity to be observed, and the time course by which
the brain resident cells become affected. Ultimately, simple
cell models cannot accurately portray the haematoma expan-
sion or many of the complex mechanisms of primary and
secondary injury, hence why they are so often performed
alongside in vivo rodent studies.
Small Mammalian Models
The most widely used animals for experimental ICH research
are rodents. Although rabbit models also exist, they are pre-
dominantly used for subarachnoid haemorrhage research, and
as such, will not be discussed here [35–38]. A PubMed as-
sessment of the literature using the search terms ‘intracerebral
haemorrhage in rats’ and ‘intracerebral haemorrhage in mice’
identified 497 studies published since 2015. These studies
could further be divided into two categories: those
characterising the pathophysiology of ICH (n = 303); and
those evaluating candidate therapies (n = 194). Despite a large
number of the latter reporting beneficial effects, none of the
treatments have as yet translated successfully to the clinic.
Based on these observations, it would appear therefore that
the current translational pipeline is not working. The vast ma-
jority of rodent ICH models are non-spontaneous and involve
invasive techniques to generate a bleed, through stereotaxic
injection of autologous blood or collagenase, and thus do not
precisely mimic the human disease, as described below.
Autologous Blood Injection Model
The autologous blood injection model was developed as a
controllable and reproducible animal model of ICH, and has
undergone many cycles of optimisation since its introduction
in 1984. Previously, Ropper et al. had used arterial blood from
a donor rat injected into the right caudate nucleus of a recipient
rat in order to observe differences in regional blood flow [39].
The use of donor blood quickly became obsolete, leading to
the advent of autologous blood taken from the femoral artery
before injection into the caudate nucleus [40]. Currently, the
most successful model involves a stereotactic injection of au-
tologous blood at two stages into the caudate nucleus. This
double injection, first implemented in 1996, was used to allow
a small amount of blood to clot, in order to prevent backflow
along the needle track, enabling the remaining volume of
blood to emulate the haematoma [41]. Following its success
in rats, the model has also been implemented for use in mice,
where similar effects have been elicited [42–44].
This model is useful at recapitulating a single bleed, which
is easily reproducible, and mimics many of the key traits ob-
served in the human condition, such as mass effect, brain
oedema, neurological deficits and neuroinflammation [42,
43, 45, 46]. The neuroinflammatory response includes innate
immune cell infiltration, activation of brain resident immune
cells, oxidative DNA damage and pro-inflammatory cytokine
release, all of which have been identified as potential thera-
peutic targets [43]. However, the autologous blood model
lacks the spontaneous nature of haemorrhage, and cannot be
used to research haematoma expansion, which is present in 1/
3 of patients during the first 24-h post-ictus [7]. Therefore, the
primary use of the autologous blood model is to investigate
the direct effects of haemotoxicity on the brain.
Collagenase Injection
The collagenase model is the most commonly employed tech-
nique for inducing ICH in rodents. This involves the injection
of collagenase, a metalloproteinase that degrades interstitial
and basement membrane collagen, into the brain via stereo-
tactic injection [47]. Collagenase causes disruption of the bas-
al lamina of the desired cerebral arteries, resulting in blood
leaking through the vessels, first achieved in rats by
Rosenberg and colleagues in 1990 [47]. Bleeding was ob-
served from 10-min post-injection, with the haematoma vol-
ume correlating to the concentration of collagenase used.
Various alterations to this model can be made depending on
the research question. For example, different brain locations
can be injected, although the most commonly used is the right
basal ganglia, which reflects the high proportion (35–70%) of
patients who develop a ‘deep’ bleed [48, 49].
As with the autologous blood injection, there are caveats
associated with the collagenase model, primarily revolving
around the potential neuroinflammatory properties of the en-
zyme [50, 51]. However, in vitro studies have demonstrated
that collagenase alone does not activate microglia, alter pros-
taglandin E2 production or induce apoptosis [51, 52].
Furthermore, in comparison to the autologous blood model,
there is not an increased neuro-immune response attributed to
collagenase, as both models display comparable temporal pat-
terns of inflammation [52, 53]. Another disadvantage with the
collagenase model is the difficulty in obtaining a relevant
sham. Current practice uses a sham model where saline is
injected into the brain [54]. However, one could argue that a
better sham would be through injection of inactivated colla-
genase into the brain, thus controlling for potential
collagenase-induced inflammation.
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Comparative studies between the autologous blood and
collagenase model have several key findings. The collagenase
injection produces a greater primary injury, most likely attrib-
uted to the haematoma expansion which can occur in this
model. Interestingly, despite autologous blood generating a
more concentrated blood volume and greater initial mass ef-
fect, the collagenase model still induces more cell death, oe-
dema and inflammation [45, 55]. There is conflicting literature
regarding neurological impairment, which is suggested to be
more sustained in the collagenase model, thus rendering it
advantageous when observation of long-term deficits of ICH
is desirable [45]. Contrastingly, another group saw more long
-term motor impairments in the autologous blood model [55].
Ultimately, choice of model depends on the research question
being asked. However, the translational relevance of these
models has been called into question, thus reiterating the need
to develop less invasive and more spontaneous techniques, or
coupling these models with other experimental methods in an
attempt to more closely recapitulate human ICH [20].
Spontaneous Haemorrhage Models
Although less common, there are rodent models that haemor-
rhage spontaneously, thus negating the need for surgery, and
potentially mimicking the clinical risk factors of ICH more
closely. As such, these may be considered as more
translationally relevant pre-clinical models, although the loca-
tion of the bleed and haematoma size cannot be controlled and
are often inconsistent between animals, as opposed to the sur-
gically induced ICH models. The main models discussed in
this section represent major risk factors for ICH in patients:
hypertension, cerebral amyloid angiopathy (CAA) and cere-
bral small vessel disease (CSVD). The HEADS committee
also highlighted the need to develop models of modifiable
and non-modifiable risk factors, such as alcoholism and age-
ing to further understand how ICH can be prevented in these
populations, as there are relatively few papers which utilise
these risk factors [20, 56–63].
Hypertension
In the 1970s, Okamoto and Aoki generated the spontaneously
hypertensive stroke prone (SHRSP) rat model, associated with
cerebral lesions that encompassed a wide range of
microinfarcts, petechial haemorrhages and larger haemorrhages
in locations such as the cerebellum [64, 65]. Furthermore, after
the addition of a high salt diet or inhibitor of nitric oxide syn-
thase Nω-nitro-L-arginine methyl ester hydrochloride (L-
NAME), the SHRSP rats exhibited larger haemorrhagic events,
which were coupled with ischaemia in the L-NAME-treated
animals [66, 67]. Ahmad found that after L-NAME treatment,
angiotensin receptor antagonist delayed the onset of stroke,
thus identifying a potential pathway which may be implement-
ed in hypertension-induced stroke [67].
Following on from the SHRSP rats, Lida and colleagues
were the first group to engineer a model of spontaneous ICH
in hypertensive mice, where the location of the bleeds identi-
fied were similar to those found clinically, such as the brain
stem, cerebellum and basal ganglia [65]. Chronic hyperten-
sion was achieved by creating a double mutant, overexpress-
ing the human renin and angiotensinogen genes. The mutants
were also fed a high salt diet, coupled with L-NAME. A ca-
veat with this study was the survival rates of these mice, which
all died within 10 weeks, thereby preventing the ability to
observe full recovery following ICH.
The same group then modelled hypertension using a non-
transgenic approach by adding L-NAME to the drinking water
to induce chronic baseline hypertension, followed by infusion
of angiotensin II or norepinephrine to generate an acute hy-
pertensive spike, which was successful at inducing ICH in
similar clinical locations to their previous study [65, 68].
This spontaneous model has been valuable in increasing the
mechanistic understanding of hypertensive ICH, with partic-
ular focus on the role of superoxide and lysyl hydroxylase 3,
and how targeting these may act as an intervention to prevent
ICH in hypertensive populations [69, 70]. Furthermore,
RNAseq analysis from the cerebral vessels of this hyperten-
sive mouse model identified potential key biomarkers for
hypertension-induced ICH, including cancer-related path-
ways, mitochondrion and MHC II proteins, which may help
with ICH diagnosis, although these observations need to be
confirmed in hypertensive ICH patients [71].
CAA
Rodent models of CAA differ predominantly in the mutated
region of the amyloid precursor protein (APP) gene, but they
all develop amyloid deposits that bind to the blood vessels and
disrupt neurovascular integrity. CAA is a large risk factor for
ICH patients above 70 years old; therefore, to mimic the clinical
scenario, older animals are utilised in these studies. [14,
20].Winkler et al. were the first group to show that mutations
in APP23mice overexpressing APP751 with the Swedish double
mutation (K670N/M671L) under the control of a neuron-
specific-Thy-1 promoter, exhibited evidence of brain haemor-
rhage in 27-month old mice [72]. The haemorrhage sites corre-
lated with the CAA vessels, providing rationale for CAA being
the driving force behind vessel rupture and bleeds in these trans-
genic mice. Similarly, a Dutch mutation mouse (E693Q) was
generated in the same way, also using APP751. These mice
exhibited haemorrhages at 29 months, although the location
and frequency of bleeds were not described [73]. Following
on from this, a Swedish, Dutch and Iowa (D694N) triple-
mutant AβPP770 mouse was produced, also developing
microbleeds [74]. Whilst the frequency of these bleeds was
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low, this could be due to the mice being sacrificed at 12 months,
and so with a longer life span, it is possible that occurrence of
bleeds would have increased. Another study using the Swedish
double mutation highlighted the significant increase in the num-
ber of microbleeds between 15- and 24-month old mice, further
reiterating the need to prolong experimentation when using
these models [75].
Some groups have explored the combination of CAA mice
and hypertension, which illustrates the importance of investi-
gating multiple risk factors for ICH together, as a patient will
often present with a number of comorbidities which can work
synergistically to cause a bleed. Over-expression of APP695
with the Swedish mutation replicated Alzheimer’s pathology,
whilst L-NAME treatment and a brief angiotensin II infusion
created chronic hypertension. Subsequently, transient acute
hypertension was generated by daily doses of angiotensin II.
The resulting hypertensive CAA mice had an increased sus-
ceptibility to spontaneous ICH at 15 months old [76]. Whilst
this is very successful at producing an all-encompassing spon-
taneous model, major caveats are associated with increased
technical demand of generating sufficient hypertension,
coupled with the prolonged study time.
Col4a1
Collagen type IV is an integral part of the basement mem-
brane, and is pivotal in providing structural support to tissues.
Mutations in the isoform COL4A1 have been identified in
CSVD, haemorrhagic stroke (particularly in younger individ-
uals), familial porencephaly and aneurysm formation of the
carotid artery [77]. Newborn mice with mutations in Col4a1/
a2 also exhibit haemorrhage phenotypes. Similarly, older
mice experience structural defects in large calibre arteries, as
observed in the descending aortae, where focal separation of
the endothelium from the media altered the vascular smooth
muscle and endothelial cell function. It is hypothesised this
may also occur in other large calibre arteries such as the ca-
rotid, andmay provide rationale for the increased likelihood of
ICH in these animals [77]. Another group recreated different
Cola4a1/a2 mutations in mice to understand the genetics and
mechanisms that can lead to bleeding, in the hope to improve
patient prognosis and treatment for the specific mutations
[78]. They also identified several modifiable risk factors
which may increase the risk of developing an ICH in this
population, such as anticoagulant treatment, acute exercise
and vaginal delivery at birth, although these factors would
need to be considered on an individual basis, rather than a
blanket statement for all COL4A1 patients [78]. Recently, a
Col4a1 mutant mouse model has been used to mimic deep
spontaneous haemorrhages which can occur in patients [79].
A novel segment (transitional segment) was identified be-
tween arterioles and capillaries which was hypermuscularised
in the mutant mice, thought to play a role in the development
of ICH due to subsequent increased intravascular pressure in
the upstream feeding arteriole. This study also utilised post-
mortem (PM) brain tissue from deep ICH fatalities to corrob-
orate the mouse data. Therefore, this study is a prime example
of how using different systems (i.e., mouse models + PM
material) can increase confidence in the translational rele-
vance of pre-clinical discoveries.
Despite poor clinical translation in terms of new treatments,
the usefulness of both surgical and spontaneous ICH models
cannot be disputed, as they have proven vital in studying the
multi-faceted effects of ICH within a whole organism. Rodent
ICHmodels have provided the ability to investigate the effects
of neurotoxic insults from blood, the infiltrating immune re-
sponse, neurological deficits and behavioural alterations.
However, with the autologous blood and collagenase model,
the surgical procedures required to do this are highly invasive
and have limitations on how well they truly mimic the clinical
scenario. Indeed, the side effects relating to the stress associ-
ated with anaesthesia and surgery will undoubtedly confound
some aspects of downstream outcome analysis. Moreover, in
the past, a disadvantage of rodent models was the presence of
the mammalian skull preventing observation of the patho-
physiology in real time. However, now various imaging tech-
niques can be implemented such as MRI, PET and laser-
speckle. Whilst MRI is commonly used following ICH-
induced surgery to view haematoma expansion and/or resolu-
tion, and laser speckle to characterise the dynamic changes in
blood flow, they are not utilised in identifying bleeds in spon-
taneous models [55, 80–84]. This is especially apparent in the
long-term studies associated with CAA, where the brain is not
observed until the animal is 2–3 years old. Prussian blue stain-
ing of hemosiderin in the brain is the sole marker used for
identifying cerebral bleeds, so the timing of the vessel rupture
is largely unknown [72–75]. Furthermore, spontaneous
models are rarely used for drug testing, which would be useful
to find preventative treatments, or to alleviate symptoms fol-
lowing a bleed, especially as a large proportion of ICH pa-
tients suffer from the risk factors modelled in these animals.
Zebrafish Models
Some of the limitations associated with the in vitro and rodent
models can be compensated for by the emerging use of
zebrafish (Danio rerio) models, which can be thought of as
an intermediate between in vitro and higher order in vivo sys-
tems. Zebrafish possess many benefits as an in vivo model,
such as rapid development, transparency of embryos and lar-
vae, non-invasive in vivo imaging and ease of genetic manip-
ulation [85]. Furthermore, as a vertebrate species, the
zebrafish genome shares ~ 70% homology with humans thus
making them an advantageous system to complement mam-
malian models [86]. We recognise that zebrafish larvae are
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developing animals, and different disease mechanisms may
exist in comparison to adult humans. However, we have
shown that key characteristics associatedwith the pathological
response to blood in the brain are apparently conserved be-
tween young fish and adult humans, suggesting they can be
reliably used to model aspects of ICH [87, 88].
In terms of ICH, one of the primary benefits of using
zebrafish larvae is that the haemorrhage is produced in a
non-invasive manner, thus arguably mimicking the spontane-
ous nature of human ICH more closely than the surgical ro-
dent models. Several different genetically modified lines exist
where haemorrhages are established in this way, whilst chem-
ical induction is another common approach for inducing a
brain bleed. There are 2 primary mechanisms by which a
bleed can be induced: blood brain barrier (BBB) defects and
weakness in the developing blood vessels. With the former,
mutations in notch3, a regulator in brain pericyte proliferation
can result in impaired BBB function and increased frequency
of brain haemorrhages [89]. As such, this model may also be
useful for studying aspects of CSVD.
Nascent cranial vessel weakness is induced by targeting
components important in the stabilisation and development
of the cerebrovasculature. βPix is a protein encoded for by
the gene arhgef7b, thought to play a role in vascular
stabilisation. Mutation of βPix results in ICH and hydroceph-
alus in zebrafish larvae, thus generating the nickname ‘bub-
blehead’ for these fish/alleles [90]. Similarly, mutation of the
Pak2a protein results in a different, though comparable
zebrafish model of ICH, known as the ‘redhead’ mutant
[91]. Defects in primary cilium attached to endothelial cells
have been shown to disrupt cerebral-vascular integrity,
resulting in ICH in the intraflagellar transport mutant [92].
Aside from genetic alterations to evoke weakness in the
neurovasculature, pharmacological agents can be utilised to in-
duce a haemorrhage in zebrafish larvae viawater bath incubations
and absorption. Statins are most commonly used for this and act
by inhibiting the cholesterol biosynthesis rate limiting enzyme 3-
hydroxy-3-methylglutaryl-coA reductase (HMGCR). This leads
to altered signalling via geranylgeranyl pyrophosphate (GGPP)
and reduces activation of Rho GTPases, which act to regulate
vascular permeability [93, 94]. Importantly, transient gene knock-
down of hmgcra using a morpholino (MO) phenocopies, the
haemorrhages were observed with statin treatment [94].
Targeting HMGCR not only provides a quick and reliable meth-
od of inducing ICH in zebrafish larvae, but may also afford in-
sight into the clinical association between hypocholesterolaemia
and increased ICH risk [95–99]. However, statin treatment has
been shown to alter myogenesis in developing zebrafish larvae
alongside reducing locomotion and heartbeat, which could poten-
tially confound other mechanistic studies which aim to focus
solely on the effects of ICH on the larvae [100].
Furthermore, there are rare genetic conditions associated
with ICH which cannot be accurately represented in rodents,
but can be in zebrafish. An example of this is the rare autoso-
mal recessive interferonopathy: Aicardi-Goutières syndrome
subtype 5 (AGS5). Mutations in the viral restriction factor
protein SAM and HD domain containing Deoxynucleoside
Triphosphate Triphosphohydrolase 1 (SAMHD1) produce
an exaggerated type I interferon (IFN) response and cerebro-
vascular disease in some patients [101–105]. Rodent models
of AGS5 exist, but these mice lack any overt physical pheno-
type [106, 107]. Contrastingly, a MO knockdown of the
samhd1 gene in zebrafish larvae resulted in spontaneous
ICH and a significant upregulation of type I IFN [108].
Similar to AGS, another genetic autoimmune disease has been
characterised in zebrafish: deficiency of Adenosine
Deaminase 2 (ADA2). ADA2 encompasses systemic inflam-
mation and a vascular phenotype arising in childhood, which
can result in ischaemic or haemorrhagic cerebral events. A
mouse orthologue of the gene encoding ADA2 (CECR1) does
not exist; however, zebrafish express two paralogues of the
CECR1 gene: cecr1a and cecr1b. Following MO knockdown
of cecr1b, these morphants exhibited intracranial bleeding,
thus alluding to a role of ADA2 in cranial vessel development
or integrity [109].
The use of zebrafish as a disease modelling tool is increas-
ing, and as previously mentioned, they possess several key
benefits for studying ICH. However, this is not to suggest that
zebrafish should replace any of the well-established models,
rather we propose that they should be utilised alongside other
in vitro and in vivo studies. For example, using zebrafish for
large-scale drug screens, and taking forward the positive hits
to interrogate further in mammalian models may increase ef-
ficiency of drug development. Furthermore, this approach
may also have ethical implications by reducing the numbers
of mammals used for primary drug screens. Zebrafish repre-
sent a powerful model system for large drug screening studies
because of their relatively high-throughput nature, and the
high conservation of drug binding sites [110]. There are, how-
ever, some caveats associated with zebrafish larval models,
such as the lack of skull preventing changes in intracranial
pressure and mass effect to be observed following ICH. In
addition, as recovery rates are so rapid in zebrafish larvae as
demonstrated by Crilly et al., it poses questions on how this
may differ to recovery in adult humans. However, understand-
ing these types of processes following ICH during develop-
ment may provide clues into how we might consider recover-
ing the aged human brain in the future [87].
Larger Mammalian Models
One recurring issue with the animal models described above is
their size in comparison to humans, and thus it is difficult to
assure accurate translation because of obvious structural differ-
ences between rodents, zebrafish and human brains. One
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approach to address this is through the use of larger animal
species, with brains more comparable to humans, in terms of
size, white:grey matter ratios and the presence of gyri. The only
2 species discussed in this section are ovine and swine models;
however, this is not to purposefully ignore any additional large
mammalian models of ICH. The use of monkeys, canines and
cats to study ICH has become largely obsolete, due mainly to
ethical considerations [111, 112]. As the main premise of this
review is to encourage collaborations between different ICH
disciplines, it was thought best to include only those species
which are widely used and more broadly accessible.
Boltze and colleagues [113] recently replicated the autolo-
gous blood model in adult sheep, observing similar histopath-
ological observations as found in rodent models, such as brain
resident cell recruitment and axonal damage. Whilst this pre-
liminary study was used to demonstrate how ovine models can
be used as a successful pre-clinical model of ICH, in the future,
it is hoped that they will provide additional translational bene-
fits when studying surgical interventions, for example like those
performed in the MISTIE and STITCH trials [113–118]. Such
candidate intervention techniques are infrequently implemented
in other pre-clinical models, and due to the small size of brain
and skull, it may be more desirable to perform these types of
surgical intervention techniques in an animal model with a larg-
er head [37, 119, 120]. Furthermore, as an aside, this was one of
the few pre-clinical ICH studies to include both male and fe-
male animals, which as determined by the HEADS initiative
needs to be performed more frequently across species, as it is
unethical to automatically exclude half of the world’s popula-
tion because female experimental outcomes may differ from
males [20]. The other existing pre-clinical studies
experimenting on female animals have been used to mainly
view hormonal differences between sexes and also how various
treatment alters outcome following ICH [82, 121–125].
Swine models of both autologous blood and collagenase
injection are implemented for many of the same reasons as
ovine models, most notably when characterising the primary
injury phase, as comparable haematoma volumes to humans
can be produced, making it more beneficial to studymass effect
and the mechanism of oedema formation in these larger ani-
mals [126–128]. In addition, drug treatments can also be tested
in swine models, such as the iron chelator deferoxamine, where
it was shown to reduce perihaematomal iron accumulation,
neuronal cell death and white matter injury, comparable to its
effects in a rat model of ICH [129]. However, the recent i-DEF
clinical trial on deferoxamine gave rise to neutral results, thus
we should utilise these larger mammalian models to optimise
treatment protocols before clinical trials, such as determining
the most effective way to administer a drug [130].
Surgical intervention has already been tested in a swine
model, whereby following an autologous blood injection, tis-
sue plasminogen activator (tPA) was added to lyse the clot,
and the haematoma was aspirated out of the brain, resulting in
a significant reduction in oedema [131]. Aside from primary
injury, functional changes which occur during ICH can also
be measured in the swine model, including alterations within
the primary somatic evoked potentials and the resulting corti-
cal spreading depression, which were found to be similar to
what was found in a rat model previously [132].
Use of farm animals in ICH research is extremely impor-
tant to understand the pathophysiology that occurs in a larger
brain. However, one limitation of these models in comparison
to rodents relates to a relative lack of behavioural assays cur-
rently available for measuring neurological outcomes.
Furthermore, due to most pre-clinical research being directed
towards rodents, it means there is a scarcity of species-specific
reagents available for other models, such as sheep, pig and
zebrafish, perhaps hindering the ability to look at the second-
ary injury response as thoroughly as can be observed in mice
and rats [128]. The experimentation time is often longer than
that of rodent work due to the use of older animals, leading to
increased costs, and imaging capabilities are essential. The
latter requires infrastructure and resources that few centres
currently have.
Post-Mortem/Ex Vivo Studies
Ex vivo studies using PM brain tissue from patients who have
died from ICH are surprisingly infrequent, but represent a
precious and most clinically relevant source of material.
Fortunately, in some instances, what is observed in human
samples is comparable to findings in pre-clinical models, as
seen in a small proportion of studies [79, 133, 134]. Aside
from comparative studies, Wu and colleagues looked at the
expression levels of nuclear factor-kappa B (NF-κB), macro-
phage inflammatory protein-2 (MIP-2) and matrix
metalloproteinase-9 (MMP9) using immunohistochemistry.
This was successful in enhancing understanding of the time
course of brain inflammation following ICH in PM tissues
[135]. Furthermore, the robust nature of PM tissue means it
can be used for purposes other than just viewing the morpho-
logical and cellular characterisation of ICH brains, as demon-
strated by a group who performed RNAseq analysis on the
frontal and occipital lobes to understand gene expression in
hereditary cerebral haemorrhage with amyloidosis-Dutch type
(HCHWA-D) [136].
Whilst researching the effect of stroke on the brain is par-
amount, studies which utilise stroke patient blood can be ex-
tremely useful for immune profiling and ‘omics-based analy-
ses. This was recently performed by Stamova and colleagues
who used RNA from both ischaemic and haemorrhagic stroke
patients to reinforce the molecular differences between each
condition [137]. Moreover, examining serum from ICH pa-
tients has identified the dysregulation of various pro and anti-
inflammatory proteins, which have also been confirmed in
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rodent ICH models [70, 138, 139]. Additionally, Taylor et al.
used ICH patient plasma to determine the role of TGF-β1
following haemorrhage. This ex vivo approach was coupled
with both in vitro and in vivo experiments, demonstrating the
power of using multiple models/systems, to corroborate dis-
coveries and increase confidence in their validity [30].
Similarly, Lu et al. have recently utilised these three pre-
clinical model systems when investigating the effects of the
microRNA miR-181c following ICH [140].
There are, however, some problems with PM brain tissue,
dependent on factors outside of the researchers’ control, such
as the availability of particular brain regions, and also the time
that the brain is fixed following death [135, 141]. The latter
was shown to cause potential exaggeration of glial cell swell-
ing, which is thought to be attributed to the fixation process in
devitalised tissue, also seen in delayed fixation in rat brain
[141]. Ultimately, the number of studies using PM and
ex vivo tissue is minimal. Future work should focus on incor-
porating these valuable resources into studies, which may be-
come more accessible if cross-discipline collaborations devel-
op, for example, between basic scientists and brain banks.
Conclusion
In this review, we have discussed the multiple models of ICH
that exist to inform about a highly disabling condition, current-
ly with no specific medical treatment. To facilitate successful
translation in the future, it is clear that there needs to be greater
collaboration within the pre-clinical ICH research community
to enable cross-talk between studies using different models and
by utilising the advantages of each system. The most common
multi-model papers exhibit experimentation on rodent and
in vitro systems. Moving forward, we suggest a bi-directional
2- or 3-pronged approach for pre-clinical ICH research. For
example, using the autologous blood injection rodent model,
the thrombin in vitro model, and also incorporating an ex vivo
element to the study, as so elegantly illustrated by both Taylor,
Lu and colleagues recently [30, 140]. These studies illustrate
the power of using multiple systems to investigate a particular
question, an approach that will hopefully become more fre-
quently adopted for translational ICH research. Moreover, as
one of the key criteria identified by the HEADS committee, we
also believe it is essential for pre-clinical findings to be tested
and verified in at least two different species (and not both
rodents) [20]. By replicating the effect of a drug or compound
identified in a smaller animal model in a higher order species
such as sheep or pig, it increases the confidence that such a
treatment may be efficacious in humans and worthy of consid-
eration for clinical investigation. Furthermore, it is also appar-
ent that the use of brain banks for PM tissue has not been
utilised enough for ICH research. Human PM tissue is ideal
to validate data obtained from animal models whilst also ad-
vancing our understanding of the human pathology and how it
may be targeted. Therefore, the use of PM tissue should be
implemented when possible, and can work in conjunction with
any of the other models (see Fig. 2). Similarly, serum from ICH
patients is also understudied, again reinforcing the need for
increased cross-talk between pre-clinical scientists and clini-
cians to obtain this type of material, and to understand key
differences which may be observed between comorbid popu-
lations which go on to develop an ICH and those that do not.
This work would feed into the other pre-clinical work taking
place, and can provide validity for the other models, if similar
Fig. 2 Multidirectional pipeline
of preclinical ICH research. In
this pipeline, there is both a
feedforward and a feedback loop,
to ensure any new findings are
valid and observed across
multiple models. In addition, the
use of post-mortem and ex vivo
tissue should feedback into all
other pre-clinical models in an
attempt to maintain clinical rele-
vance. Fostering multi-discipline
collaborations increases the like-
lihood of creating a drug which
will be successful in humans, es-
pecially if it is shown to exert
positive effects across the pipe-
line. Maximal advantages are de-
noted above each model/system
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trends are observed. By fostering collaborations with different
disciplines, it will strengthen the depth and breadth of ICH
research, andwill increase the chances of finding new treatment
options for ICH patients in the future.
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